RT Journal Article
SR Electronic
T1 A prevaccination validated network that drives the breadth of the protective neutralizing antibody response following Dengue Vaccine TV003 immunization
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.25.21264123
DO 10.1101/2021.09.25.21264123
A1 Pelletier, Adam Nicolas
A1 Sanchez, Gabriela
A1 Watson, Mark
A1 Izmirly, Abdullah
A1 Di Pucchio, Tiziana
A1 Haddad, Elias
A1 Paramithiotis, Eustache
A1 Khalil, Jorge
A1 Diamond, Michael
A1 Kallas, Esper
A1 Sekaly, Rafick Pierre
YR 2021
UL http://medrxiv.org/content/early/2021/09/28/2021.09.25.21264123.abstract
AB Development of fully protective dengue virus (DV) vaccines has been problematic as infection with DV requires a broad antibody immune response that targets all 4 possible serotypes. Herein, we used an integrated systems vaccinology approach to identify prevaccination features that allow the development of fully protective DV-specific antibody responses. This approach allowed us to identify a transcription network in a subset of monocytes defined by the expression of CD68 and downstream of specific pro- and anti-inflammatory cytokines. Moreover, we identified metabolites as drivers of an immune response that induced neutralizing antibodies to the 4 DV serotypes. Specifically, PC/PE drove the production of TGF-B in CD68 low monocytes, which was a positive correlate of the protective antibody response. In contrast, primary and secondary bile acids triggered a proinflammatory response downstream of TGR5 signaling and inflammasome activation in CD68 high monocytes, which was associated to a non-protective antibody response. These features were validated in vitro in primary myeloid cells. Our results highlight the role of cell and systemic metabolism as regulators of protective immune responses to vaccination, and that systems vaccinology is a key tool to identify such mechanisms.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01696422Funding StatementFunding was obtained from the NIH (project number 7R01AI125202-06) named A multi-tiered approach to develop validated assays to predict efficacy of a tetravalent live attenuated Dengue Virus vaccine in Phase II and Phase III clinical trials.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was processed by the Butantan Institute, in Sao Paolo Brazil.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not yet public, will be made public shortly with associated accession numbers in the manuscript.